Victoria Socha

DocwireNews

In patients with heart failure, sodium-glucose cotransporter-2 (SGLT2) inhibitors improve renal and cardiovascular outcomes. There is growing evidence that SGLT2 inhibition decreases the risk of acute kidney injury (AKI). Jananya Wattanakul and colleagues, of the Bhumibol Adulyadej Hospital, Bangkok, Thailand, conducted a study to examine the effect of SGLT2 inhibitors on biomarkers of tubular injury in patients with acute heart failure.Results of the study were reported during a poster session at the American Society of Nephrology Kidney Week 2023. The poster was titled SGLT2 Inhibitor Dapagliflozin Reduces Biomarkers of Tubular Injury in Patients With Acute Heart Failure.The study cohort included patients who were hospitalized for acute heart failure. Patients were randomized to receive dapagliflozin added to standard therapy or to a control group for 28 days. The primary outcome of interest was the change of urinary biomarkers ([TIMP-2] &times; [IGFBP7]) by NephroCheck from baseline. Secondary outcomes included the incidence of AKI, change in serum creatinine from baseline, adverse events (AEs), and 28-day mortality.Thirty-two patients underwent randomization. After 7 days, compared with the control group, dapagliflozin significantly reduced urinary biomarkers ([TIMP-2] &times; [IGFBP7]): dapagliflozin, &ndash;0.03 (ng/mL)2 per 1000 versus control, +0.04 (ng/mL)2 per 1000; P=.022. The trend continued to the end of the study period.Compared with the control group, there was a trend toward a decrease in AKI events in the dapagliflozin group (33.3% vs 46.2%; P=.0513). The two groups were similar in change in serum creatinine, AEs, and 28-day mortality.&ldquo;Initiation of SGLT2 inhibitors in patients with acute heart failure significantly decreased the urinary AKI risk markers TIMP-2 and IGFBP7 and supported the protective effect of SGLT2 inhibitors on renal tubular injury,&rdquo; the researchers said.Source: Wattanakul J, Gojaseni P, Chittinandana A. SGLT2 inhibitor dapagliflozin reduces biomarkers of tubular injury in patients with acute heart failure. TH-PO059. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2023; November 2, 2023; Philadelphia, Pennsylvania.

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Latest News

Renal Effects of SGLT2 Inhibitors in Patients With Acute Heart Failure

ASN Kidney Week 2023

Compared with the control group, there was a trend toward a decrease in AKI events in the dapagliflozin group (33.3% vs 46.2%; P=.0513). 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe